best buy microsoft office for mac cheap fireworks mac cost of final cut pro x buying anydvd after using pirate cheapest microsoft windows 7 ultimate 64 bit windows 7 professional licensing buy photoimpact x3 buying nero 10 australia buy money 2002 price of microsoft expression studio buying mountain lion buy coreldraw graphics suite x4 buy office visio standard 2003 buy windows server 2008 r2 foundation buy office 2008 mac standard buy autocad 2000 price of windows 7 professional oem cheap adobe indesign cs4 for mac cheap adobe cs4 software cheap rosetta stone french 1 purchase filemaker pro mac buy office 2003 enterprise buy office 2007 licence online buy bento 3 uk buy autodesk ecotect analysis buy adobe photoshop elements 5.0 price of office 2010 professional plus in india buy matlab compiler purchase aperture 3 upgrade buy microsoft excel 2007 online

Tag Archive | "cisplatin"

Low-dose IMRT may be safe for patients with HPV-positive head and neck cancer

Tuesday, June 3, 2014

0 Comments

Source: www.oncologypractice.com Author: Laura Nikolaides Lower-dose radiation therapy may be safe for some patients with human papillomavirus (HPV)-positive oropharyngeal cancer, decreasing the risk of often long-term side effects, such as trouble swallowing, dry mouth, loss of taste, neck stiffness, and thyroid problems, investigators reported at the annual meeting of the American Society of Clinical Oncology. […]

Continue reading...

Aspirin may stop deafness caused by chemotherapy

Sunday, May 11, 2014

0 Comments

Source:  www.bbc.com Author: staff Aspirin could save the hearing of cancer patients receiving chemotherapy, scientists in Cardiff hope. A trial will be launched at the city’s Velindre Hospital to see if high doses of the drug can prevent permanent loss. Conditions ranging from tinnitus to deafness are a common side effect for patients given the […]

Continue reading...

Experimental EGFR inhibitor added nothing but rash

Wednesday, March 19, 2014

0 Comments

Source: www.oncologypractice.com Author: Neil Osterweil, Oncology Report Digital Network The addition of the experimental targeted agent zalutumumab to primary curative chemoradiation for head and neck cancers did not improve locoregional control, disease-specific survival, or overall survival at 3 years of follow-up. The only thing that zalutumumab added to therapy was a skin rash in the […]

Continue reading...

Chemoradiation offered better survival than accelerated radiation in head and neck squamous cell carcinomas

Wednesday, March 19, 2014

0 Comments

Source: www.oncologypractice.com Author: Neil Osterweil, Oncology Report Digital Network Concurrent chemoradiation offered better overall survival and disease-free survival than accelerated radiotherapy in patients with moderately advanced squamous cell carcinomas of the head and neck, investigators reported at the Multidisciplinary Head and Neck Symposium. Actuarial rates of 2-year overall survival and disease-free survival in patients treated […]

Continue reading...

PTEN loss, PIK3CA mutation predicted resistance to cetuximab in HNSCC

Monday, June 3, 2013

0 Comments

June 2, 2013 Source: Helio.com   CHICAGO — PTEN loss or PIK3CA mutation predicted resistance to treatment with cisplatin plus cetuximab in a cohort of patients with head and neck squamous cell carcinoma, according to phase 3 study results presented at the ASCO Annual Meeting. “Cetuximab is the only targeted therapy in use in head […]

Continue reading...

Are combination therapies effective for advanced SCCHN?

Tuesday, March 12, 2013

0 Comments

Source: Author: DrBicuspid Staff In a recent study, researchers from the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center examined whether the addition of multiple drugs to radiation therapy is superior to the current standard of care therapy with one drug and radiation for locally advanced squamous cell carcinoma of the head and neck […]

Continue reading...

Targeted Drugs No Help in Head and Neck Cancer

Thursday, March 7, 2013

0 Comments

Source: medpagetoday.com Author: Charles Bankhead, Staff Writer, MedPage Today Date: March 05, 2013     The addition of targeted agents to standard chemotherapy failed to improve efficacy in two different trials of advanced head and neck cancer. In one trial, patients given gefitinib (Iressa) in addition to docetaxel lived about a month longer than those […]

Continue reading...

Erbitux add-on falls short in esophageal cancer

Monday, January 28, 2013

0 Comments

Source: www.medpagetoday.com Author: Charles Bankhead, Staff Writer, MedPage Today The addition of a targeted agent to definitive chemoradiation failed to improve survival in an unselected population with esophageal cancer, a randomized trial showed. In fact, patients who received cetuximab (Erbitux) with chemoradiation had significantly worse overall survival (OS) reflected in a 50% increase in the […]

Continue reading...

Ten year results of landmark neck cancer trial published

Friday, November 30, 2012

0 Comments

Source: www.modernmedicine.com Author: Gabriel Miller The latest data from a trial that opened in 1992 confirm that for locally advanced laryngeal cancer, sequential and concomitant chemoradiotherapy each produce similar survival rates, but the concomitant approach more often allows the larynx to be preserved. When the results of RTOG 91-11 were first published in 2003. “they […]

Continue reading...

Neoadjuvant chemo does not improve oral cancer survival rates

Sunday, November 11, 2012

0 Comments

Source: www.drbicuspid.com Author: DrBicuspid Staff Patients with advanced resectable oral squamous cell carcinoma (OSCC) who undergo surgery do not benefit from improved survival after induction with docetaxel, cisplatin, and fluorouracil (TPF), according to a new study (Journal of Clinical Oncology, November 5, 2012). Study author Zhi-yuan Zhang, MD, PhD, from Shanghai Jiao Tong University School […]

Continue reading...